Cargando…
Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
Autores principales: | Sriwijitalai, Won, Wiwanitkit, Viroj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373499/ https://www.ncbi.nlm.nih.gov/pubmed/30468431 http://dx.doi.org/10.4274/tjh.galenos.2018.2018.0397 |
Ejemplares similares
-
Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases
por: Eren, Rafet, et al.
Publicado: (2018) -
Interference in the indirect antiglobulin test and direct
antiglobulin test from rheumatoid factor
por: Xu, Lei, et al.
Publicado: (2019) -
False Negative Fecal Occult Blood Test: Prozone Effect
por: Sookaromdee, Pathum, et al.
Publicado: (2019) -
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018) -
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)